Uncategorized

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

Nona Biosciences announced today that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies Read More »

Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus

Turn Therapeutics launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.

Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus Read More »

PharmAbcine’s U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024

PharmAbcine, Inc. announced that its U.S. subsidiary, Wincal Biopharm, Inc. (“WincalBio”), gained agreat attention at the world’s largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.

PharmAbcine’s U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024 Read More »

Scroll to Top